Disseminated nocardiosis after cladribine treatment for relapsing remitting multiple sclerosis: a case report

[1] Torkildsen Ø(2016)Disease-modifying treatments for multiple sclerosis - a review of approved medications Eur J Neurol. 23 18-27

[2] Myhr KM(2015)Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis Pract Neurol 15 273-279

[3] Bø L(2016)Multiple sclerosis, a treatable disease Clin Med (Lond) 16 s53-s59

[4] Scolding N(2010)Clarity study group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis N Engl J Med. 362 416-26

[5] Barnes D(2009)Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis Eur J Neurol 16 409-412

[6] Cader S(2018)Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study Mult Scler 24 1594-1604

[7] Doshi A(2017)Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis Mult Scler 23 872-874

[8] Chataway J(2016)Fulminant central nervous system nocardiosis in a patient treated with alemtuzumab for relapsing-remitting multiple sclerosis JAMA Neurol 73 757-759

[9] Giovannoni G(2021)Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications J Neurol Neurosurg Psychiatry 92 177-188

[10] Comi G(2020)Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate Mult Scler 26 1227-1236

[1] Torkildsen Ø(2016)Disease-modifying treatments for multiple sclerosis - a review of approved medications Eur J Neurol. 23 18-27

[2] Myhr KM(2015)Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis Pract Neurol 15 273-279

[3] Bø L(2016)Multiple sclerosis, a treatable disease Clin Med (Lond) 16 s53-s59

[4] Scolding N(2010)Clarity study group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis N Engl J Med. 362 416-26

[5] Barnes D(2009)Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis Eur J Neurol 16 409-412

[6] Cader S(2018)Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study Mult Scler 24 1594-1604

[7] Doshi A(2017)Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis Mult Scler 23 872-874

[8] Chataway J(2016)Fulminant central nervous system nocardiosis in a patient treated with alemtuzumab for relapsing-remitting multiple sclerosis JAMA Neurol 73 757-759

[9] Giovannoni G(2021)Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications J Neurol Neurosurg Psychiatry 92 177-188

[10] Comi G(2020)Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate Mult Scler 26 1227-1236